BACKGROUND: Friedreich ataxia is a progressive neurodegenerative disorder affecting afferent cerebellar pathways and other neuronal systems, including afferent visual pathways. A systematic clinical outcome measure for examination of visual dysfunction in Friedreich ataxia has not been identified. We sought to identify a simple, reliable method for assessing clinical and subclinical visual dysfunction in patients with Friedreich ataxia. METHODS: Contrast letter acuity was measured binocularly in Friedreich ataxia patients and age-matched visually asymptomatic volunteers (control group) using the Low-contrast Sloan Letter Charts at three different low-contrast levels (5.0%, 1.25%, and 0.6%). Binocular high-contrast visual acuity (100% level) was also determined for each participant. RESULTS: Despite equal median binocular high-contrast visual acuities between the two groups, patients with Friedreich ataxia had significantly lower (worse) Low-contrast Sloan Letter Chart scores compared with controls, particularly at the lowest contrast levels (1.25% and 0.6%). Ambulation status significantly predicted Low-contrast Sloan Letter Charts scores in linear regression models accounting for patient age, suggesting a potential complementary role for Low-contrast Sloan Letter Chart testing in the assessment of disease status as well as visual function in Friedreich ataxia. CONCLUSIONS: This study demonstrates that Low-contrast Sloan Letter Chart testing may provide a useful clinical outcome measure for Friedreich ataxia and other neuro-ophthalmologic disorders.
BACKGROUND:Friedreich ataxia is a progressive neurodegenerative disorder affecting afferent cerebellar pathways and other neuronal systems, including afferent visual pathways. A systematic clinical outcome measure for examination of visual dysfunction in Friedreich ataxia has not been identified. We sought to identify a simple, reliable method for assessing clinical and subclinical visual dysfunction in patients with Friedreich ataxia. METHODS: Contrast letter acuity was measured binocularly in Friedreich ataxiapatients and age-matched visually asymptomatic volunteers (control group) using the Low-contrast Sloan Letter Charts at three different low-contrast levels (5.0%, 1.25%, and 0.6%). Binocular high-contrast visual acuity (100% level) was also determined for each participant. RESULTS: Despite equal median binocular high-contrast visual acuities between the two groups, patients with Friedreich ataxia had significantly lower (worse) Low-contrast Sloan Letter Chart scores compared with controls, particularly at the lowest contrast levels (1.25% and 0.6%). Ambulation status significantly predicted Low-contrast Sloan Letter Charts scores in linear regression models accounting for patient age, suggesting a potential complementary role for Low-contrast Sloan Letter Chart testing in the assessment of disease status as well as visual function in Friedreich ataxia. CONCLUSIONS: This study demonstrates that Low-contrast Sloan Letter Chart testing may provide a useful clinical outcome measure for Friedreich ataxia and other neuro-ophthalmologic disorders.
Authors: David R Lynch; Massimo Pandolfo; Jorg B Schulz; Susan Perlman; Martin B Delatycki; R Mark Payne; Robert Shaddy; Kenneth H Fischbeck; Jennifer Farmer; Paul Kantor; Subha V Raman; Lisa Hunegs; Joanne Odenkirchen; Kristy Miller; Petra Kaufmann Journal: Mov Disord Date: 2012-12-12 Impact factor: 10.338
Authors: Lauren A Seyer; Kristin Galetta; James Wilson; Reiko Sakai; Susan Perlman; Katherine Mathews; George R Wilmot; Christopher M Gomez; Bernard Ravina; Theresa Zesiewicz; Khalaf O Bushara; S H Subramony; Tetsuo Ashizawa; Martin B Delatycki; Alicia Brocht; Laura J Balcer; David R Lynch Journal: J Neurol Date: 2013-06-18 Impact factor: 4.849
Authors: Maya Patel; Charles J Isaacs; Lauren Seyer; Karlla Brigatti; Sarah Gelbard; Cassandra Strawser; Debbie Foerster; Julianna Shinnick; Kimberly Schadt; Eppie M Yiu; Martin B Delatycki; Susan Perlman; George R Wilmot; Theresa Zesiewicz; Katherine Mathews; Christopher M Gomez; Grace Yoon; Sub H Subramony; Alicia Brocht; Jennifer Farmer; David R Lynch Journal: Ann Clin Transl Neurol Date: 2016-07-25 Impact factor: 4.511
Authors: Ali G Hamedani; Lauren A Hauser; Susan Perlman; Katherine Mathews; George R Wilmot; Theresa Zesiewicz; S H Subramony; Tetsuo Ashizawa; Martin B Delatycki; Alicia Brocht; David R Lynch Journal: Neurol Genet Date: 2018-07-23
Authors: Ashley McCormick; Jennifer Farmer; Susan Perlman; Martin Delatycki; George Wilmot; Katherine Matthews; Grace Yoon; Chad Hoyle; Sub H Subramony; Theresa Zesiewicz; David R Lynch; Shana E McCormack Journal: Ann Clin Transl Neurol Date: 2017-07-26 Impact factor: 4.511
Authors: Thomas Ihl; Ella M Kadas; Timm Oberwahrenbrock; Matthias Endres; Thomas Klockgether; Jan Schroeter; Alexander U Brandt; Friedemann Paul; Martina Minnerop; Sarah Doss; Tanja Schmitz-Hübsch; Hanna G Zimmermann Journal: Cerebellum Date: 2020-08 Impact factor: 3.847